Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not ...
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless ...
There’s a war brewing over blockbuster weight loss medications — and patients ... Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name ...
VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, ...
The Eli Lilly deal includes a "real-world" study into how its weight-loss drugs impact "participants' employment status and sick days," among other factors. LONDON — U.S. pharmaceutical giant ...
A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for ...
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback